Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Irma Damen"'
Autor:
Soumitra Roy, Theo Schouten, Irma Damen, Katarina Radosevic, Pascal de Jong, Lies Bogaert, Cindy Swett-Tapia, Vladimir van Hoek, Myra N. Widjojoatmodjo, Roland Zahn, Dirk Spek, Patrick Wanningen, Jerome Custers
Publikováno v:
Journal of General Virology. 97:2117-2128
Recombinant measles virus (rMV) vectors expressing heterologous viral membrane protein antigens are potentially useful as vaccines. Genes encoding the mumps virus haemagglutinin-neuraminidase (MuV-HN), the influenza virus haemagglutinin (Flu-HA) or t
Autor:
Dan H. Barouch, Keith G. Mansfield, Bonnie A. Ewald, Anna R. Thorner, Peter Abbink, Kara L. O'Brien, Angela Carville, Ronald Vogels, Shirley Smits, Angelique A. C. Lemckert, Lennart Holterman, Irma Damen, Jaap Goudsmit, Diana M. Lynch, Matthew Denholtz, Menzo J. E. Havenga
Publikováno v:
Journal of virology, 81(9), 4654-4663. American Society for Microbiology
Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently being developed for both human immunodeficiency virus type 1 and other pathogens. The potential limitations associated with rAd5 vectors, however, have led to the constructi
Autor:
Katarina Radosevic, Menzo J. E. Havenga, Angelique A. C. Lemckert, Irma Damen, Martijn Sieuwerts, David Michael Hone, Jorn Kaspers, Jaap Goudsmit, M. van Meerendonk, R. van der Vlugt, Frank Weichold, Dan H. Barouch, Yasir A. W. Skeiky, Ratna Mintardjo, Ronald Vogels, David Zuijdgeest, Jerry Sadoff, Stefanie Mueller, Lennart Holterman, Gert Gillissen
Publikováno v:
Journal of general virology, 87(Part 8), 2135-2143. Society for General Microbiology
Adenoviral vectors based on adenovirus type 35 (rAd35) have the advantage of low natural vector immunity and induce strong, insert-specific T- and B-cell responses, making them prime-candidate vaccine carriers. However, severe vector-genome instabili
Autor:
Angelique A. C. Lemckert, Jos M. Grimbergen, Irma Damen, Marco G. Cecchini, Germaine Penders, Niels Helmus, David Zuijdgeest, Michelle van Meerendonk, Wouter Koudstaal, Olga J.A.E Ophorst, Abraham Bout, Richard van Rijnsoever, Jaap Goudsmit, Antoinette Wetterwald, Björn F. Koel, Eric Hartkoorn, Marie-Pierre de Béthune, Ronald Vogels, Stefan Kostense, Laura Panitti, Mieke Caroline Sprangers, Menzo J. E. Havenga, Paul H.A. Quax
Publikováno v:
Journal of virology, 77(15), 8263-8271. American Society for Microbiology
Journal of Virology, 15, 77, 8263-8271
Journal of Virology, 15, 77, 8263-8271
Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However, preexisting immunity against Ad5 hampers consistency of